

- [125] Khan S, Chatfield S, Stratford R, Bedwell J, Bentley M, Sulsh S, et al. Ability of SPI2 mutant of *S. typhi* to effectively induce antibody responses to the mucosal antigen enterotoxigenic *E. coli* heat labile toxin B subunit after oral delivery to humans. *Vaccine* 2007;25:4175-82.
- [208] Gordon MA. Salmonella infections in immunocompromised adults. *J Infect* 2008;56:413-22.
- [209] Parry CM. Typhoid Fever. *Curr Infect Dis Rep* 2004;6:27-33.
- [210] Levine MM. Typhoid fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines* 5th ed: Saunders-Elsevier, 2008: 887-914.
- [211] Parry C, Wain J, Chinh NT, Vinh H, Farrar JJ. Quinolone-resistant *Salmonella typhi* in Vietnam. *Lancet* 1998;351:1289.
- [212] Mermin JH, Villar R, Carpenter J, Roberts L, Samariddin A, Gasanova L, et al. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. *J Infect Dis* 1999;179:1416-22.
- [213] Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. *Trans R Soc Trop Med Hyg* 2004;98:423-30.
- [214] Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ* 2004;82:346-53.
- [215] Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. *Emerg Infect Dis* 2005;11:326-9.
- [216] DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. *N Engl J Med* 2007;357:1069-71.
- [217] Ochiai RL, Acosta CJ, Agtini M, Bhattacharya SK, Bhutta ZA, Do CG, et al. The use of typhoid vaccines in Asia: the DOMI experience. *Clin Infect Dis* 2007;45 Suppl 1:S34-8.
- [218] Chaignat C, Clemens J, Favorov M, Klugman K, Kariuki S, Levine MM. Report of the Typhoid Immunization Group to SAGE. Geneva: WHO SAGE meeting; 2007 November 2007.
- [219] Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, et al. Typhoid fever in travelers: who should be targeted for prevention? *Clin Infect Dis* 2004;39:186-91.
- [220] Clemens J, Hoffman S, Ivanoff B, Klugman K, Levine MM, Neira M, et al. Typhoid fever vaccines. *Vaccine* 1999;17:2476-8.
- [221] Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. *Vaccine* 2006;24:3804-11.
- [222] DeRoeck D, Ochiai RL, Yang J, Anh DD, Alag V, Clemens JD. Typhoid vaccination: the Asian experience. *Expert Rev Vaccines* 2008;7:547-60.
- [223] Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR, et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. *Public Health* 2006;120:1081-7.
- [224] Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, et al. Revaccination with locally-produced Vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings. *Pediatr Infect Dis J* 2007;26:1001-5.
- [225] Lim SM, Jung HS, Kim MJ, Park DW, Kim WJ, Cheong HJ, et al. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. *J Microbiol Biotechnol* 2007;17:611-5.
- [226] Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of *Salmonella typhi* Vi capsular polysaccharide vaccine three years after immunization. *Vaccine* 1996;14:435-8.

- [227] Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. *Eur J Clin Microbiol Infect Dis* 1999;18:609-20.
- [228] Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. *Bull World Health Organ* 2001;79:625-31.
- [229] Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. *Infect Immun* 1999;67:5806-10.
- [230] Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. *N Engl J Med* 2001;344:1263-9.
- [231] Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. *Vaccine* 1999;17 Suppl 2:S22-7.
- [232] Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. *Clin Infect Dis* 2007;45 Suppl 1:S24-8.
- [233] Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. *FEMS Microbiol Rev* 2002;26:339-53.
- [234] Hohmann EL, Oletta CA, Killeen KP, Miller SI. *phoP/phoQ*-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. *J Infect Dis* 1996;173:1408-14.
- [235] Witherell GW. Oral typhoid vaccine. *Acambis/Berna. Curr Opin Investig Drugs* 2003;4:1010-8.
- [236] Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. *J Infect Dis* 2005;192:360-6.
- [237] Lankowski AJ, Hohmann EL. Killed but metabolically active Salmonella typhimurium: application of a new technology to an old vector. *J Infect Dis* 2007;195:1203-11.